Abbott's strong second-quarter sales offset by acquisition costs
This article was originally published in Scrip
Executive Summary
Abbott Laboratories has reaffirmed its full-year EPS guidance after its second-quarter sales jumped by 18% to $8.8 billion, but acquisition and related costs dragged on its net income.